Is Sacituzumab govitecan a targeted drug?

Sacituzumab govitecan is an antibody-drug conjugate (ADC) that induces DNA damage-mediated cell death by targeting cancer cells expressing TROP-2. Metastatic triple-negative breast cancer (mTNBC) is an aggressive breast cancer with limited treatment options with cytotoxic chemotherapy drugs. Targeted chemotherapy through the application of antibody drug conjugates (ADCs) is the latest advancement in cancer treatment. Gosatuzumab is a targeted drug that combines a humanized antitrophoblast surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.

The TROPiCS-02 trial demonstrated a 3.2-month overall survival (OS) benefit of gosatuzumab versus TPC (single-agent chemotherapy, median OS: 14.4 months versus 11.2 months) in patients with metastatic HR+ and HER2-negative breast tumors. In this study, gosatuzumab reduced the risk of disease progression or death by 34%. Median PFS was 5.5 months, not 4 months. Gosatuzumabhas also been approved by the U.S. Food and Drug Administration (FDA) for patients with metastatic HR+ and HER2-negative breast cancer.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.